Icosavax to Participate in in Upcoming Investor Conferences
November 08 2022 - 8:00AM
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases and a vision
of creating pan-respiratory vaccines for older adults, today
announced that the company will participate in and host one-on-one
meetings at the following investor conferences:
Guggenheim 4th Annual Immunology and
Neurology Conference
- Icosavax will
present on Tuesday, November 15 at 9:00 am ET
Jefferies London Healthcare
Conference
- Icosavax will
participate in a Fireside Chat on Thursday, November 17 at 6:20 am
ET
Interested parties can access the live audio
webcast for this conference from the Investor Relations section of
the company's website at www.icosavax.com. The webcast replays will
be available following the conclusion of the presentations for
approximately 90 days.
About Icosavax
Icosavax is a biopharmaceutical company
leveraging its innovative VLP platform technology to develop
vaccines against infectious diseases, with an initial focus on
life-threatening respiratory diseases and a vision for combination
and pan-respiratory vaccines. Icosavax’s VLP platform technology is
designed to enable multivalent, particle-based display of complex
viral antigens, which it believes will induce broad, robust, and
durable protection against the specific viruses targeted.
Icosavax’s pipeline includes vaccine candidates targeting
respiratory syncytial virus (RSV) and human metapneumovirus (hMPV),
as well as programs in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and influenza. Icosavax was formed in
2017 to advance the breakthrough VLP technology from the Institute
for Protein Design at the University of Washington with the goal to
discover, develop, and commercialize vaccines against infectious
diseases. Icosavax is located in Seattle.
For more information,
visit www.icosavax.com.
Media Contact: Jessica
Yingling, Ph.D. Little Dog Communications Inc.
jessica@litldog.com858.344.8091
Investor Contact:Laurence
WattsGilmartin Group, LLClaurence@gilmartinir.com619.916.7620
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Sep 2023 to Sep 2024